Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials

BACKGROUND: Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin‐4 and interleukin‐13. International phase II and III studies have evaluated the efficacy and safety of dupilumab in adults with moderate‐to‐severe atopic dermatitis (AD), but the effects of dupilumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Katoh, N., Kataoka, Y., Saeki, H., Hide, M., Kabashima, K., Etoh, T., Igarashi, A., Imafuku, S., Kawashima, M., Ohtsuki, M., Fujita, H., Arima, K., Takagi, H., Chen, Z., Shumel, B., Ardeleanu, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384164/
https://www.ncbi.nlm.nih.gov/pubmed/31564057
http://dx.doi.org/10.1111/bjd.18565

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384164/
https://www.ncbi.nlm.nih.gov/pubmed/31564057
http://dx.doi.org/10.1111/bjd.18565

Ejemplares similares